A Novel Thermal Method to Inactivate Rotavirus for Use in Vaccines

Rotavirus is a highly contagious, diarrhea-inducing pathogen that annually causes approximately 250,000 deaths worldwide and millions of hospitalizations, especially afflicting infants and young children. One strategy to combat this virus is through vaccination. Continuing safety and efficacy concerns with the currently existing live, oral vaccines against rotavirus have led researchers to search for alternative treatment approaches, such as vaccines containing inactivated rotavirus.

This technology describes a method for inactivating rotavirus. Traditional inactivation strategies use chemicals that reduce antigenicity (by altering rotavirus proteins), leading to less protection against the virus. Conversely, this method preserves and/or maintains the integrity of viral particles, leading to greater protection against rotavirus. This strategy has been validated in mice, piglets and cattle and further clinical studies are underway.

Potential Commercial Applications: Competitive Advantages:
  • An inactivated rotavirus virus vaccine
  • Can inactivate potential adventitious agents that might contaminate vaccines
  • Animal studies thus far show greater protection against rotavirus than currently available vaccines
  • No formalin or beta-propiolactone required for inactivation of rotavirus
  • Greater antigenicity of treated particles compared to chemically treated particles
  • Technique preserves and maintains integrity of virus particles

Related Invention(s):


Baoming Jiang (CDC)  ➽ more inventions...

Roger Glass (CDC)  ➽ more inventions...

Jean-Francois Saluzzo (CDC)  ➽ more inventions...

Intellectual Property:
U.S. Pat: 8,357,525 issued 2013-01-22
PCT Application No. PCT/US2008/075239
US Application No. 12/676,490
US Application No. 13/718,648
US Application No. 15/725,221

Jiang B., et al. PMID: 18382129
Westerman L., et al. PMID: 1129131
Saluzzo JF, et al. PMID: 3146583

Collaboration Opportunity:

The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: A Novel Thermal Method to Inactivate Rotavirus for Use in Vaccines. For collaboration opportunities, please contact CDC TTO at tto@cdc.gov or 1-404-639-1330

Licensing Contact:
Karen Surabian, J.D., M.B.A.
Email: karen.surabian@nih.gov
Phone: 301-594-9719

OTT Reference No: E-153-2013/0
Updated: Feb 8, 2018